AusCann Group Holdings (ASX:AC8) aims to bring Australian patients access to high quality, cost effective, cannabinoid medicines.
Market size / potential in Australia is with chronic (3.8M patients) & neuropathic pain sufferers (1.8M patients). Cannabinoid medicines offer many benefits including a reduction in side effects / opiates.
Challenges to its use include education of Australian Medical Community and AusCann are using the Canadian Market as blueprint.
- Canadian expert Dr Daniel Schecter appointed Chief Medical Advisor
- Medical outreach program
- Liaison Managers
- Mentorship program
- Online courses
In Canada, the market has grown from 8000 patients in 2014 with its introduction to 170k+ patients in 2017 and is projected to increase to over 500k+ patients projected by 2021
Focus for the year ahead: Importing Canadian product from Canadian company Canopy Growth Corp, increasing understanding of the benefits among Australian Doctors and increasing its prescription, application for Australian licences to grow local product.
Copyright 2017 - Finance News Network